Dr. Reddy's Laboratories Share Price (NYSE: RDY)

$14.2

▲

-0.01

(-0.07%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Dr. Reddy's Laboratories Stock chart to analyse performance

Dr. Reddy's Laboratories stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$14.14
Today's High:$14.32
$14.20
0.42%
Downside
Day's Volatility :1.22%
Upside
0.8%
52 Weeks Low:$12.26
52 Weeks High:$16.41
$14.20
13.66%
Downside
52 Weeks Volatility :25.31%
Upside
13.49%

Dr. Reddy's Laboratories Stock Returns

Period	Dr. Reddy's Laboratories Ltd.	Sector (Health Care)	Index (Russel 2000)
3 Months	-3.66%	3.6%	0.0%
6 Months	11.29%	-7.7%	0.0%
1 Year	-12.45%	-12.6%	0.0%
3 Years	36.64%	8.4%	-3.0%

Dr. Reddy's Laboratories Ltd. Key Stats

Check Dr. Reddy's Laboratories key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$14.21
Open	$14.14
Today's High	$14.315
Today's Low	$14.14
Market Capitalization	$12.0B
Today's Volume	$920.3K
52 Week High	$16.414
52 Week Low	$12.26
Revenue TTM	$334.3B
EBITDA	$89.4B
Earnings Per Share (EPS)	$0.78
PE Ratio	18.21
Dividend Yield	0.64%
Profit Margin	16.99%
Quarterly Earnings Growth YOY	0.02%
Return On Equity TTM	17.71%

Stock Returns calculator for Dr. Reddy's Laboratories Stock including INR - Dollar returns

The Dr. Reddy's Laboratories stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Dr. Reddy's Laboratories investment value today

Current value as on today

₹92,830

Returns

₹7,170

(-7.17%)

Returns from Dr. Reddy's Laboratories Stock

₹12,454 (-12.45%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Dr. Reddy's Laboratories Stock

-3.42%

Period: Aug 1, 2025 to Aug 31, 2025. Change in 30 Days versus previous period

Investment in Dr. Reddy's Laboratories Shares from India has dropped by -3.42% over the past 30 days, indicating reduced transactional activity.

-15%

Period: Aug 1, 2025 to Aug 31, 2025. Change in 30 Days versus previous period

Search interest for Dr. Reddy's Laboratories Stock from India on INDmoney has decreased by -15% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Dr. Reddy's Laboratories Ltd.

Name
Holdings %
Name
Holdings %
Robeco Institutional Asset Management BV
1.46%
Renaissance Technologies Corp
1.10%
Royal Bank of Canada
1.09%
Morgan Stanley - Brokerage Accounts
1.05%
BlackRock Inc
1.02%
Aikya Investment Management Ltd
0.76%

Analyst Recommendation on Dr. Reddy's Laboratories Stock

Rating

Trend

Buy

42%Buy

30%Hold

27%Sell

Based on 40 Wall street analysts offering stock ratings for Dr. Reddy's Laboratories(by analysts ranked 0 to 5 stars)

Dr. Reddy's Laboratories Share Price Target

What analysts predicted

Upside of 7.4%

Target:

$15.25

Current:

$14.20

Dr. Reddy's Laboratories share price target is $15.25, a slight Upside of 7.4% compared to current price of $14.20 as per analysts' prediction.

Dr. Reddy's Laboratories Stock Insights

Price Movement
In the last 7 days, RDY stock has moved down by -1.8%
Increasing Revenue
Revenue is up for the last 6 quarters, 70.83B → 85.45B (in $), with an average increase of 3.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 15.93B → 14.17B (in $), with an average decrease of 11.0% per quarter
RDY vs NBIX (1 yr)
In the last 1 year, Neurocrine Biosciences Inc. has given 9.9% return, outperforming this stock by 24.8%
Price to Sales
ForRDY every $1 of sales, investors are willing to pay $0.2, whereas for Neurocrine Biosciences Inc., the investors are paying $5.6 for every $1 of sales.

Dr. Reddy's Laboratories Ltd. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Revenue	$2.3B	↑ 13.49%
Net Income	$261.4M	↑ 3.74%
Net Profit Margin	11.17%	↓ 1.05%

	FY21	Y/Y Change
Revenue	$2.6B	↑ 8.66%
Net Income	$236.7M	↓ 11.59%
Net Profit Margin	9.09%	↓ 2.08%

	FY22	Y/Y Change
Revenue	$2.8B	↑ 13.0%
Net Income	$309.2M	↑ 36.72%
Net Profit Margin	10.99%	↑ 1.9%

	FY23	Y/Y Change
Revenue	$3.0B	↑ 14.69%
Net Income	$548.0M	↑ 91.22%
Net Profit Margin	18.33%	↑ 7.34%

	FY24	Y/Y Change
Revenue	$3.4B	↑ 13.54%
Net Income	$670.6M	↑ 23.56%
Net Profit Margin	19.95%	↑ 1.62%

	FY25	Y/Y Change
Revenue	$3.8B	↑ 16.61%
Net Income	$653.7M	↑ 1.54%
Net Profit Margin	17.37%	↓ 2.58%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$852.9M	↓ 1.83%
Net Income	$157.4M	↓ 5.21%
Net Profit Margin	18.45%	↓ 0.66%

	Q2 FY24	Q/Q Change
Revenue	$919.1M	↑ 8.33%
Net Income	$166.8M	↑ 6.5%
Net Profit Margin	18.14%	↓ 0.31%

	Q3 FY24	Q/Q Change
Revenue	$956.6M	↑ 4.48%
Net Income	$149.8M	↓ 9.82%
Net Profit Margin	15.66%	↓ 2.48%

	Q4 FY24	Q/Q Change
Revenue	$983.5M	↑ 4.27%
Net Income	$166.3M	↑ 12.59%
Net Profit Margin	16.91%	↑ 1.25%

	Q1 FY25	Q/Q Change
Revenue	$983.4M	↑ 1.76%
Net Income	$184.3M	↑ 12.77%
Net Profit Margin	18.74%	↑ 1.83%

	Q2 FY25	Q/Q Change
Revenue	$85.5B	↑ 0.46%
Net Income	$14.2B	↓ 11.04%
Net Profit Margin	16.59%	↓ 2.15%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Profit	$1.3B	↑ 12.68%

	FY21	Y/Y Change
Profit	$1.4B	↑ 9.65%

	FY22	Y/Y Change
Profit	$1.5B	↑ 10.44%

	FY23	Y/Y Change
Profit	$2.5B	↑ 78.3%

	FY24	Y/Y Change
Profit	$2.0B	↓ 19.39%

	FY25	Y/Y Change
Profit	$2.2B	↑ 16.39%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$499.5M	↓ 1.71%

	Q2 FY24	Q/Q Change
Profit	$555.2M	↑ 11.72%

	Q3 FY24	Q/Q Change
Profit	$570.0M	↑ 3.07%

	Q4 FY24	Q/Q Change
Profit	$577.2M	↑ 2.69%

	Q1 FY25	Q/Q Change
Profit	$546.4M	↓ 3.65%

	Q2 FY25	Q/Q Change
Profit	$48.6B	↑ 2.89%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$400.0M	↑ 3.96%
Investing Cash Flow	$-66.0M	↓ 36.29%
Financing Cash Flow	$-337.2M	↑ 17.97%

	FY21	Y/Y Change
Operating Cash Flow	$490.2M	↑ 19.64%
Investing Cash Flow	$-311.1M	↑ 360.29%
Financing Cash Flow	$-4.1M	↓ 98.82%

	FY22	Y/Y Change
Operating Cash Flow	$368.8M	↓ 21.27%
Investing Cash Flow	$-346.2M	↑ 16.45%
Financing Cash Flow	$-31.8M	↑ 712.75%

	FY23	Y/Y Change
Operating Cash Flow	$715.9M	↑ 109.45%
Investing Cash Flow	$-503.1M	↑ 56.79%
Financing Cash Flow	$-326.6M	↑ 1009.04%

	FY24	Y/Y Change
Operating Cash Flow	$547.1M	↓ 22.83%
Investing Cash Flow	$-485.1M	↓ 2.63%
Financing Cash Flow	$-45.3M	↓ 85.99%

	FY25	Y/Y Change
Operating Cash Flow	$536.7M	↑ 2.19%
Investing Cash Flow	$-671.4M	↑ 44.17%
Financing Cash Flow	$218.6M	↓ 602.55%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$138.7M	↑ 143.19%
Investing Cash Flow	$-136.7M	-
Financing Cash Flow	$-6.4M	↓ 110.09%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$101.8M	↓ 26.25%
Investing Cash Flow	$-242.6M	↑ 78.4%
Financing Cash Flow	$114.3M	↓ 1890.06%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$111.2M	↑ 9.65%
Investing Cash Flow	$-227.6M	↓ 5.81%
Financing Cash Flow	$192.7M	↑ 69.27%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$77.9M	↓ 28.94%
Investing Cash Flow	$-64.2M	↓ 71.38%
Financing Cash Flow	$6.9M	↓ 96.35%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$254.3M	↑ 232.27%
Investing Cash Flow	$-153.8M	↑ 143.68%
Financing Cash Flow	$-85.2M	↓ 1349.15%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$14.6B	↓ 33.49%
Investing Cash Flow	$-19.2B	↑ 44.3%
Financing Cash Flow	$-1.2B	↓ 83.68%

Dr. Reddy's Laboratories Technicals Summary

Sell

Neutral

Buy

Dr. Reddy's Laboratories is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Dr. Reddy's Laboratories Ltd. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Dr. Reddy's Laboratories Ltd.	2.97%	11.29%	-12.45%	36.64%	19.03%
Haleon Plc Spon Ads	3.05%	-7.37%	-3.54%	74.07%	32.25%
United Therapeutics Corporation	4.14%	-1.7%	-13.52%	36.72%	71.39%
Zoetis Inc.	3.02%	-8.29%	-14.8%	-0.37%	-5.4%
Neurocrine Biosciences Inc.	9.03%	21.94%	11.59%	35.52%	20.41%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Dr. Reddy's Laboratories Ltd.	18.21	18.21	3.13	70.93	0.18	0.1	0.01	420.56
Haleon Plc Spon Ads	21.78	21.78	3.17	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	11.89	11.89	1.43	26.59	0.19	0.13	NA	158.65
Zoetis Inc.	26.97	26.97	2.53	6.33	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	41.3	41.3	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Dr. Reddy's Laboratories Ltd.	Buy	$12.0B	19.03%	18.21	16.99%
Haleon Plc Spon Ads	Buy	$43.9B	32.25%	21.78	13.81%
United Therapeutics Corporation	Buy	$13.8B	71.39%	11.89	40.36%
Zoetis Inc.	Buy	$69.3B	-5.4%	26.97	27.83%
Neurocrine Biosciences Inc.	Buy	$13.8B	20.41%	41.3	13.88%

Dr. Reddy's Laboratories Dividend announcements

Dr. Reddy's Laboratories Dividends September, 2025
In the quarter ending September,2025. Dr. Reddy's Laboratories has declared dividend of $0.09

About Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad, Telangana, India. Founded in 1984 by Dr. K. Anji Reddy, the company provides a wide range of pharmaceuticals in India and over 25 countries worldwide. Dr. Reddy's Laboratories operates in various segments, including generic medicines, active pharmaceutical ingredients (APIs), custom pharmaceutical services, biosimilars, and differentiated formulations. The company's portfolio includes products for therapeutic areas such as gastroenterology, cardiovascular, diabetology, oncology, pain management, and dermatology. Dr. Reddy's Laboratories is listed on the NYSE under the ticker symbol RDY, making its American Depositary Receipts (ADRs) available to U.S. investors. Known for its commitment to innovation, quality, and affordability, Dr. Reddy's Laboratories continues to deliver comprehensive healthcare solutions and improve the lives of patients globally. Currently Dr. Reddy's Laboratories ADR has a market cap of $13.73 Billion. It has a P.E ratio of 0.0. The shares of Dr. Reddy's Laboratories ADR are trading at $14.2 .

Organization	Dr. Reddy's Laboratories
Employees	27811
CEO	Mr. Motupalli Venkata Ramana M.B.A.
Industry	Health Technology

Key Management of Dr. Reddy's Laboratories Ltd.

Name	Title
Mr. Gunupati Venkateswara Prasad B.E.	Co-Chairman, MD & Member of Management Council
Mr. Kallam Satish Reddy B.Tech., M.S.	Chairman of the Board & Member of the Management Council
Mr. Erez Israeli M.B.A.	CEO & Member of the Management Council
Mr. Mannam Venkatanarasimham	CFO & Member of the Management Council
Mr. Krishna K. Venkatesh B.Pharma M.S.	Global Head of Quality and Pharmacovigilance & Member of the Management Council
Mr. Deepak Sapra M.B.A.	Global Head of Pharmaceutical Services and Active Ingredients & Member of Management Council
Mr. Motupalli Venkata Ramana M.B.A.	CEO of Branded Markets - India & Emerging Countries and Member of Management Council
Ms. Archana Bhaskar B.Sc., M.B.A.	EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council
Mr. Sanjay Sharma B.Tech.	Executive VP, Global Head of Global Manufacturing & Member of Management Council
Mr. Patrick Aghanian B.A., M.B.A.	Head of Generics, Europe & Consumer Health and Member of Management Council

Important FAQs about investing in RDY Stock from India :

What is Dr. Reddy's Laboratories share price today?

Dr. Reddy's Laboratories share price today is $14.20 as on August 30, 2025 at 1:29 am IST at the close of the market. Dr. Reddy's Laboratories share today touched a day high of $14.32 and a low of $14.14.

What is the 52 week high and 52 week low for Dr. Reddy's Laboratories share?

Dr. Reddy's Laboratories share touched a 52 week high of $16.41 and a 52 week low of $12.26. Dr. Reddy's Laboratories stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $14.20, lower by 13.49% versus the 52 week high.

How to invest in Dr. Reddy's Laboratories Stock (RDY) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Dr. Reddy's Laboratories on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Dr. Reddy's Laboratories Shares that will get you 0.1056 shares as per Dr. Reddy's Laboratories share price of $14.20 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Dr. Reddy's Laboratories Stock (RDY) from India?

Indian investors can start investing in Dr. Reddy's Laboratories (RDY) shares with as little as ₹88.286 or $1 (as of September 01, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Dr. Reddy's Laboratories stock (as per the Rupee-Dollar exchange rate as on September 01, 2025). Based on Dr. Reddy's Laboratories share’s latest price of $14.20 as on August 30, 2025 at 1:29 am IST, you will get 0.7042 shares of Dr. Reddy's Laboratories. Learn more about fractional shares .

What are the returns that Dr. Reddy's Laboratories has given to Indian investors in the last 5 years?

Dr. Reddy's Laboratories stock has given 19.03% share price returns and 20.94% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?